Quantcast

Latest Oxycyte Stories

2014-05-28 12:32:20

LONDON, May 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Traumatic Brain Injury - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/research_r_d/pipeline/traumatic_brain_injury_1.html Traumatic Brain Injury - Pipeline Review, H1 2014 SummaryGlobal Markets Direct's, 'Traumatic Brain Injury - Pipeline Review, H1 2014', provides an overview of the Traumatic Brain Injury's therapeutic pipeline.This report provides comprehensive...

2014-05-12 08:27:09

NEW YORK, May 12, 2014 /PRNewswire/ -- Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) Today, approximately 8% of the world's population is over the age of 65; and that number is expected to double in less than 40 years. As the world's population ages in the coming years, the demand for critical care services will undoubtedly increase in both developed and underdeveloped countries across the world. In fact, GBI Research estimates that the size of this market will grow from $2.3 billion in...

2014-04-21 08:25:06

NEW YORK, April 21, 2014 /PRNewswire/ -- Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), an emerging competitor, is engaged in the business of developing biotechnology products in the nature of blood substitutes with a focus on oxygen delivery to tissue. It is currently developing Oxycyte(TM), a product which is a safe and effective oxygen carrier for use in surgical and similar medical situations. The Company's Oxycyte oxygen carrier product is a perfluorocarbon emulsified with water...

2011-06-02 08:00:00

FORT WORTH, Texas, June 2, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that it has acquired Regranex® Gel, along with the corresponding intellectual property (including patents), from Systagenix. Terms of the deal were not disclosed. "This acquisition is aligned with our strategic focus on building a portfolio of novel biopharmaceuticals for wound healing and tissue regeneration," said Travis E. Baugh, President and Chief Operating Officer of...

2011-03-16 15:20:00

BETHESDA, Md., March 16, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO). Taking note of the recent unusual activity in the Company's stock, Northwest Biotherapeutics (NWBT) commented today that it is not aware of any basis relating to the Company or its products or programs. The Company is continuing to move forward with the trial-related activities for its large, 240-patient clinical trial for GBM brain cancer. The patients treated with NWBT's DCVax...

2011-02-23 08:00:00

FORT WORTH, Texas, Feb. 23, 2011 /PRNewswire/ -- Healthpoint today announced the launch of a new corporate identity featuring a new company name, Healthpoint Biotherapeutics, along with an updated brandmark and corporate tagline, "The Science of Healing(TM)". Together, the new corporate identity is designed to communicate the company's commitment to scientific innovations in tissue repair and healing that will ultimately contribute to improved outcomes and quality of life for the patients...

2011-01-04 07:00:00

LAS VEGAS, Jan. 4, 2011 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (Pink Sheets: CVBT) today released summary Phase IIa and Phase IIb clinical trial data for CVBT's biological therapy to treat diabetic wounds, CVBT-141B. CVBT's Phase II data indicates that CVBT's FGF-1 biological drug appears to be delivering efficacy at a level significantly greater than has been seen in any other treatments, for patients suffering from chronic ischemic diabetic wounds. The results of the two...

2010-12-03 11:34:00

DURHAM, N.C., Dec. 3, 2010 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (Nasdaq: OXBT) (SIX Swiss Exchange: OXBT) today announced that the Company plans to report second quarter fiscal year 2011 financial results on Thursday, December 9, 2010. Oxygen's Chairman and CEO Chris Stern, and Chief Financial Officer Michael Jebsen, will host a conference call and live webcast to discuss the results on Friday, December 10, 2010 at 11 a.m. EST. To access the live teleconference dial...

2010-01-21 08:00:00

DURHAM, N.C., Jan. 21 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (Nasdaq: OXBT) chairman and CEO Chris Stern will preside over the NASDAQ Opening Bell on Friday, January 22, 2010. A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx starting at 9:20 a.m. eastern time. About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in...

2010-01-13 13:59:00

DURHAM, N.C., Jan. 13 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) announced today that the company's common stock will begin trading on the NASDAQ Capital Market with the opening of trading on Friday, January 15, 2010. The shares will continue to trade under the symbol OXBT. In addition, company chairman and CEO Chris Stern will be in New York to ring the opening bell at the NASDAQ one week later on Friday, January 22. About Oxygen Biotherapeutics,...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related